[{"_1":2,"_128":-5,"_129":-5},"loaderData",{"_3":4,"_83":84},"root",{"_5":6,"_7":8,"_9":10,"_11":12,"_68":69,"_13":70,"_71":72},"cart",["P",6],"isLoggedIn",["P",8],"footer",["P",10],"header",{"_13":14,"_28":29},"shop",{"_15":16,"_17":18,"_19":20,"_21":22,"_25":26},"id","gid://shopify/Shop/99853599055","name","KōJō","description","6 ingredients at clinical doses. Full label transparency. Once-daily supplement powder. Every dose published. No proprietary blends.","primaryDomain",{"_23":24},"url","https://www.kojo.life","brand",{"_27":-5},"logo","menu",{"_15":30,"_31":32},"gid://shopify/Menu/322106229071","items",[33,44,50,56,62],{"_15":34,"_35":-5,"_36":37,"_38":39,"_40":41,"_23":42,"_31":43},"gid://shopify/MenuItem/817501110607","resourceId","tags",[],"title","The Formula","type","HTTP","https://www.kojo.life/pages/the-formula",[],{"_15":45,"_35":-5,"_36":46,"_38":47,"_40":41,"_23":48,"_31":49},"gid://shopify/MenuItem/817501143375",[],"Why KōJō","https://www.kojo.life/pages/why-kojo",[],{"_15":51,"_35":-5,"_36":52,"_38":53,"_40":41,"_23":54,"_31":55},"gid://shopify/MenuItem/817501176143",[],"Research","https://www.kojo.life/pages/foundations",[],{"_15":57,"_35":-5,"_36":58,"_38":59,"_40":41,"_23":60,"_31":61},"gid://shopify/MenuItem/817501208911",[],"Journal","https://www.kojo.life/blogs/journal",[],{"_15":63,"_35":-5,"_36":64,"_38":65,"_40":41,"_23":66,"_31":67},"gid://shopify/MenuItem/817501241679",[],"Subscribe","https://www.kojo.life/pages/subscribe",[],"publicStoreDomain","groov-7187.myshopify.com",["P",70],"consent",{"_73":74,"_75":76,"_77":78,"_79":80,"_81":82},"checkoutDomain","www.kojo.life","storefrontAccessToken","2397ff6000827730849df646c27b33d8","withPrivacyBanner",false,"country","US","language","EN","routes/blogs.$blogHandle._index",{"_85":86},"blog",{"_38":87,"_88":89,"_90":91,"_94":95},"The Kōjō Journal","handle","journal","seo",{"_38":92,"_19":93},"The Kōjō Journal — Supplement Science and Evidence","Evidence-based articles on supplements, ingredients and nutrition. Every claim referenced. Written by the Kōjō founders.","articles",{"_96":97,"_120":121},"nodes",[98],{"_99":100,"_102":103,"_88":104,"_15":105,"_106":107,"_116":117,"_38":118,"_85":119},"author",{"_17":101},"Tom","contentHtml","

The UK nootropic market is growing fast and the claims are outpacing the science by a considerable margin. One double-blind, placebo-controlled trial of a commercially available nootropic stack found statistically significant improvements in immediate word recall — but effect sizes were modest and the sample was 73 adults. That's the honest starting point: some signal, a lot of noise, and a market that needs someone to read the actual studies.

\n\n\n

What the evidence actually shows

\n\n

I'll be direct: the word \"nootropic\" covers everything from well-studied compounds with decades of human trial data to ingredients with nothing behind them except a persuasive product page. The category is not regulated in the UK as a drug class — it's a marketing term, not a pharmacological one. Schifano et al. (2025) published a narrative overview of nootropic and \"smart drug\" use that captures this well: the spectrum runs from prescription stimulants used off-label by students, through to over-the-counter supplement stacks with genuinely mixed evidence bases.

\n\n

The one area where I think the evidence is reasonably solid is B-vitamin status and cognitive function — specifically the homocysteine pathway. Smith et al. (2017) reviewed the relationship between homocysteine, B vitamins, and cognitive impairment across multiple large cohort studies. Elevated homocysteine is associated with accelerated brain atrophy and cognitive decline, and B-vitamin supplementation may reduce homocysteine levels in people who are deficient. That's not the same as saying B vitamins make healthy people smarter — it isn't. But for people with suboptimal B-vitamin status, which is more common in the UK than most assume, the cognitive case for correcting that deficiency is reasonably supported.

\n\n

Then there's the choline question. Derbyshire et al. (2021) reviewed choline's role in neurological development and brain function across the first 1,000 days of life — compelling data for that window. But choline's relevance doesn't end at infancy. It's a precursor to acetylcholine, the neurotransmitter most directly implicated in memory and attention. Most UK adults don't consume enough of it. That's a legitimate cognitive concern, even if the direct supplementation evidence in healthy adults remains thinner than I'd like.

\n\n

What's biologically happening — the mechanisms worth understanding

\n\n

Nootropic compounds tend to work through a handful of overlapping pathways. Understanding which pathway a compound targets helps you assess whether the claim being made is plausible — or whether someone has just borrowed mechanistic language from mouse studies and applied it to a human product.

\n\n

Acetylcholine and cholinergic signalling

\n\n

Acetylcholine is the neurotransmitter most closely tied to attention, working memory, and learning consolidation. Compounds that support cholinergic signalling — either by providing precursors like choline, or by modulating acetylcholinesterase activity — are among the more mechanistically plausible cognitive targets. Tribble et al. (2025) identified choline alongside B vitamins B6, B9, and B12 as potentially neuroprotective through one-carbon metabolism pathways — research that's still developing but directionally interesting.

\n\n

Cerebral blood flow and vascular mechanisms

\n\n

Several plant-derived compounds studied in the nootropic context — including pine bark extract and grape seed extract — are thought to support cerebral blood flow through nitric oxide pathways and vascular tone. The human data here is genuinely limited, and I'd be overstating it to claim these compounds demonstrably improve cognition in healthy adults. What I can say is that the mechanistic rationale is coherent, and some preliminary research suggests they may support vascular function in ways that could be relevant to brain perfusion.

\n\n

Oxidative stress and neuronal protection

\n\n

Neurons are metabolically expensive tissue. They produce a lot of reactive oxygen species and are relatively vulnerable to oxidative damage over time. Vitamin C contributes to the protection of cells from oxidative stress — that's a registered UK nutrition and health claim — and some research suggests this may be relevant at the neuronal level, though the direct cognitive implications in healthy, non-deficient adults are less clear.

\n\n

Energy metabolism at the cellular level

\n\n

Creatine monohydrate is probably the most evidence-backed compound in this category, and it's rarely marketed as a nootropic — which is a shame, because the cognitive data is more interesting than most people realise. Creatine phosphate is a rapid ATP resynthesis substrate in the brain as well as muscle. Creatine increases physical performance in successive bursts of short-term, high-intensity exercise — that's the registered claim — but research also suggests it may support cognitive performance under conditions of mental fatigue or sleep deprivation, though the evidence in well-rested, healthy adults is more equivocal.

\n\n

Dosing — what the clinical evidence actually supports

\n\n

This is where most nootropic products quietly fall apart. You can list impressive ingredients on a label. What matters is whether the dose matches what was used in the trials showing an effect.

\n\n

Creatine monohydrate has the clearest dose-response data. Most RCTs showing cognitive and physical performance effects used 3–5g per day. The KōJō Daily Formula contains 5,000mg of micronised creatine monohydrate — that's at the upper end of what the clinical literature used, and it's the dose I'd want to be taking if I'm going to take it at all.

\n\n

Choline targets are harder to pin down because the research hasn't settled on an optimal supplemental dose for cognitive outcomes specifically. The UK adequate intake is around 400mg per day for adults, but dietary surveys suggest many people fall below this. Derbyshire et al. (2022) reviewed habitual choline intakes across childbearing years and found widespread insufficiency — a finding that likely extends to the general adult population.

\n\n

For B vitamins and the homocysteine pathway, the intervention doses in Smith et al. (2017)'s reviewed trials varied, but the key point is that supplementation only appears to matter when baseline status is suboptimal. Supplementing B vitamins when you're already replete doesn't appear to confer additional cognitive benefit. Get a blood test before assuming you need them.

\n\n

Pine bark extract and grape seed extract have been studied across a wide dose range — 50mg to 300mg per day in various trials — with inconsistent results. The human data on these compounds is thin and I'd be overstating it to claim a specific dose is established for cognitive outcomes.

\n\n

The Mind Lab Pro trial — what one actual RCT found

\n\n

There's one study I want to address directly because it gets cited a lot in UK nootropic marketing. Abbott-Imboden et al. (2023) ran a double-blind, placebo-controlled trial of Mind Lab Pro — a commercially available nootropic stack — in 73 healthy adults. They found statistically significant improvements in immediate and delayed word recall at 30 days (p < 0.05). The effect sizes were modest. The sample was small. The trial was funded by the manufacturer.

\n\n

I'm not dismissing it. A positive RCT is a positive RCT, and the methodology appears sound from what I can assess. But 73 people, one trial, manufacturer funding, and modest effect sizes on a single memory task doesn't constitute a well-evidenced base. It's a starting point. I'd want to see independent replication before drawing strong conclusions.

\n\n

What it does tell me is that multi-ingredient stacks can, in principle, produce measurable cognitive effects in controlled conditions. Whether those effects are clinically meaningful in everyday life is a separate question the study doesn't answer.

\n\n

Student and workplace use — the context most brands ignore

\n\n

Ragan et al. (2013) analysed evidence around student use of cognitive enhancers — including both prescription stimulants and OTC supplements — and raised important questions about efficacy, ethics, and safety that the supplement industry largely sidesteps. The honest answer is that most people reaching for a nootropic supplement in the UK are doing so because they're tired, stressed, or cognitively overextended. No supplement is going to fix a structural sleep deficit or chronic work overload.

\n\n

I think about high cortisol levels and sleep here — because the two are deeply connected. If your cortisol is dysregulated, your sleep architecture suffers, and if your sleep is poor, your cognitive performance will be poor regardless of what you take in the morning. Addressing the upstream cause matters more than adding a supplement on top of an unaddressed problem.

\n\n

Ingredients with ongoing research — and the honest caveats

\n\n

Several ingredients that appear in nootropic formulas — including some in KōJō's formula — have interesting mechanistic profiles but limited large-scale human trial data. I want to be clear about where the evidence stands on each.

\n\n

Glycine (2,000mg in KōJō Daily Formula) has been studied for its role in neurotransmission and sleep quality, with some preliminary research suggesting it may support sleep onset and morning alertness — but large-scale human trials are limited and the cognitive implications in healthy adults remain under investigation.

\n\n

Taurine (2,000mg) is conditionally essential, widely distributed in the brain, and has been studied in the context of neuroprotection in animal models. The human data on cognitive outcomes specifically is thin, and I'd be overstating it to claim otherwise.

\n\n

Aged garlic extract (600mg) has been studied primarily for cardiovascular endpoints. Research into any cognitive effects is ongoing and large-scale human trials in this context are limited.

\n\n

Olive leaf extract (500mg) and grape seed extract (200mg) have been studied for vascular and antioxidant properties. Some preliminary data suggests they may support circulation, which has theoretical relevance to brain perfusion — but direct cognitive outcome data from large human trials is limited.

\n\n

Pine bark extract (150mg) has the most interesting cognitive research profile of this group, with some small trials suggesting it may support attention and working memory in specific populations. Research is ongoing and I wouldn't overstate the current evidence base.

\n\n

What to look for when buying a nootropic supplement in the UK

\n\n

The UK supplement market is less regulated than most people assume. There's no requirement for pre-market efficacy testing. A company can launch a product with a compelling ingredient list and never conduct a single human trial. Here's what I actually look for.

\n\n

\nTransparent labelling: every ingredient listed with its exact dose. No proprietary blends that obscure individual amounts.
\nDoses that match the research: if an ingredient was studied at 500mg and the product contains 50mg, the trial data doesn't apply to that product.
\nClaims that match the evidence tier: registered nutrition and health claims are permitted for a reason — they've been assessed. Unregistered claims warrant scepticism.
\nThird-party testing: batch-level testing for heavy metals, microbial contamination, and label accuracy matters, especially for plant-derived extracts.
\nHonest communication about limits: any brand that implies certainty where the science is genuinely uncertain is either uninformed or choosing not to tell you something.

\n\n

Frequently asked questions

\n\n

Are nootropic supplements legal in the UK?

Yes — the vast majority of OTC nootropic supplements are legal in the UK. They're regulated as food supplements under UK food law, not as medicines. That means no pre-market efficacy testing is required. As Schifano et al. (2025) note, the category spans a wide spectrum from benign to potentially risky, depending on the specific compound.

\n\n

Do nootropic supplements actually work?

Some compounds have genuine evidence behind them; many don't. Abbott-Imboden et al. (2023) found statistically significant word recall improvements with a multi-ingredient stack in a 73-person RCT, but effect sizes were modest. The honest answer is: it depends entirely on the compound, the dose, and your baseline nutritional status.

\n\n

Is creatine a nootropic?

It's not typically marketed as one, but some research suggests creatine may support cognitive performance under conditions of mental fatigue, because the brain uses creatine phosphate for rapid ATP resynthesis just as muscle does. The evidence in well-rested, healthy adults is more limited. It remains one of the better-studied compounds in this space.

\n\n

How important is choline for brain function?

Choline is a precursor to acetylcholine, the neurotransmitter most directly implicated in memory and attention. Derbyshire et al. (2021) reviewed its role in neurological development comprehensively. Most UK adults don't consume adequate choline through diet, which makes it a legitimate cognitive consideration — though direct supplementation evidence in healthy adults is still developing.

\n\n

Should I take a nootropic supplement if I'm already eating well and sleeping enough?

If your nutrition is genuinely solid and your sleep is consistent, the marginal benefit from most nootropic supplements will be smaller. The strongest evidence for cognitive benefit from supplementation relates to correcting deficiencies — B vitamins, choline — rather than pushing beyond an already adequate baseline. Smith et al. (2017) makes this point clearly for the B-vitamin and homocysteine pathway.

\n\n

What's the difference between a nootropic and a smart drug?

Ragan et al. (2013) and Schifano et al. (2025) both address this. \"Smart drugs\" typically refers to prescription medications used off-label for cognitive purposes — modafinil being the most common UK example. Nootropic supplements are OTC products. The regulatory, safety, and evidence profiles are very different. I'd treat them as separate categories entirely.

\n\n

My honest take

\n\n

I started KōJō because I was frustrated by the gap between what supplement brands claim and what the evidence actually supports. The nootropic category is where that gap is widest.

\n\n

There are compounds I find genuinely interesting — creatine for its ATP resynthesis role in the brain, choline for its acetylcholine precursor status, B vitamins for the homocysteine pathway. These have mechanistic coherence and, in some cases, reasonable human trial data. I take them. I think they matter — particularly if your baseline status is suboptimal, which is more likely than most people assume without testing.

\n\n

But I'm sceptical of the broader nootropic marketing category. The word has become a shorthand for \"makes your brain work better\", applied to ingredients that range from well-evidenced to entirely speculative. The one RCT I find most directly relevant — Abbott-Imboden et al. (2023) — showed real but modest effects in a small sample with manufacturer funding. That's not nothing, but it's not the certainty the marketing implies.

\n\n

What I keep coming back to is this: if you're sleeping poorly, chronically stressed, or nutritionally depleted, no nootropic supplement is going to paper over that. The upstream variables matter more. Fix those first. Then, if you want to explore whether specific, well-dosed compounds move the needle for you, do it with realistic expectations and a willingness to track your own response honestly.

\n\n

I don't think supplementation is the answer to cognitive performance. I think it's one small lever among many — and only worth pulling if the bigger levers are already in place.

\n\n

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.

\n\n

References (10 studies)

\nSchifano et al. (2025) — Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and \"Smart Drug\" Use and Misuse. PMID 41007388.
\nSmith et al. (2017) — Homocysteine, B Vitamins, and Cognitive Impairment. PMID 27431367.
\nDerbyshire et al. (2021) — Choline, Neurological Development and Brain Function: A Systematic Review Focusing on the First 1000 Days. PMID 32531929.
\nTribble et al. (2025) — Dysfunctional one-carbon metabolism identifies vitamins B6, B9, B12, and choline as neuroprotective in glaucoma. PMID 40345183.
\nAbbott-Imboden et al. (2023) — Efficacy of the nootropic supplement Mind Lab Pro on memory in adults: Double blind, placebo-controlled study. PMID 37194920.
\nDerbyshire et al. (2022) — Habitual Choline Intakes across the Childbearing Years: A Review. PMID 34959942.
\nRagan et al. (2013) — Student use of cognitive enhancers: an analysis of current evidence. PMID 22732441.
\nDerbyshire (2025) — Choline in Pregnancy and Lactation: Essential Knowledge for Clinical Practice. PMID 40362867.
\nPark et al. (2025) — Association Between Dietary Intake and Blood Concentrations of One-Carbon-Metabolism-Related Nutrients in European Prospective Investigation. PMID 40573081.
\nTamura et al. (2023) — Intestinal Atp8b1 dysfunction causes hepatic choline deficiency and steatohepatitis. PMID 37990006.

\n\n

Photo via Unsplash

","nootropic-supplement-uk-what-the-evidence-shows","gid://shopify/Article/1002080829775","image",{"_15":108,"_109":110,"_23":111,"_112":113,"_114":115},"gid://shopify/ArticleImage/397466501455","altText","Daily supplement nutrition health science","https://cdn.shopify.com/s/files/1/0998/5359/9055/articles/photo-1584308666744-24d5c474f2ae_4b13bb13-e308-4ea4-9e30-a9fe74bd0050.jpg?v=1776953348","width",1200,"height",800,"publishedAt","2026-04-23T14:09:06Z","Nootropic supplement UK: what the evidence shows",{"_88":89},"pageInfo",{"_122":123,"_124":78,"_125":126,"_127":126},"hasPreviousPage",true,"hasNextPage","endCursor","eyJsYXN0X2lkIjoxMDAyMDgwODI5Nzc1LCJsYXN0X3ZhbHVlIjoxMDAyMDgwODI5Nzc1LCJvZmZzZXQiOjM2fQ==","startCursor","actionData","errors"]